MedTrace Logo

Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD

NCT02652598 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-01-19

No results posted yet for this study

Summary

The experimental design is an open-label two-week trial of tolcapone to evaluate which clinical domains are affected by tolcapone treatment and to identify "responders" to tolcapone treatment in the two subject groups (BI and NCD)

Conditions

  • Brain Injuries, Traumatic
  • Neurocognitive Disorders
  • Brain Injuries

Interventions

DRUG

Tolcapone

Sponsors & Collaborators

  • Lieber Institute for Brain Development (LIBD)

    collaborator UNKNOWN

  • Sheppard Pratt Health System

    lead OTHER

Principal Investigators

  • Robert J Schloesser, MD · Sheppard Pratt Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2020-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02652598 on ClinicalTrials.gov